Evolus (NASDAQ:EOLS) Stock Price Down 6.5% - Here's Why

Key Points

• Evolus shares fell 6.5% to about $8.01 in midday trading, with volume down 77% from the average session level.
• Analysts remain broadly optimistic, with a consensus “Moderate Buy” rating and an average price target of $14.50, well above the current share price.
• Insider David Moatazedi sold 105,108 shares worth approximately $950,000, while institutional investors own a substantial 90.69% of the company.

Evolus, Inc. (NASDAQ:EOLS - Get Free Report)'s share price fell 6.5% during mid-day trading on Thursday . The company traded as low as $8.00 and last traded at $8.0110. 239,506 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 1,033,910 shares. The stock had previously closed at $8.57.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. HC Wainwright restated a "buy" rating and set a $13.00 price objective on shares of Evolus in a research note on Tuesday, August 25th. BTIG Research reiterated a "buy" rating and issued a $13.00 target price on shares of Evolus in a research note on Wednesday, June 17th. Wall Street Zen upgraded shares of Evolus from a "hold" rating to a "buy" rating in a report on Saturday, August 8th. Finally, Weiss Ratings upgraded shares of Evolus from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, June 15th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $14.50.

Evolus Stock Performance

The firm has a market cap of $514.20 million, a PE ratio of -14.97 and a beta of 1.42. The stock has a 50-day simple moving average of $7.38 and a two-hundred day simple moving average of $6.19.

Insider Transactions at Evolus

In other Evolus news, insider David Moatazedi sold 105,108 shares of the business's stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $9.04, for a total transaction of $950,176.32. Following the completion of the sale, the insider directly owned 499,592 shares in the company, valued at $4,516,311.68. The trade was a 17.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 5.00% of the company's stock.

Hedge Funds Weigh In On Evolus

Institutional investors and hedge funds have recently made changes to their positions in the business. Sequoia Financial Advisors LLC purchased a new stake in Evolus during the second quarter valued at approximately $71,000. WINTON GROUP Ltd bought a new stake in shares of Evolus during the 2nd quarter valued at $77,000. Squarepoint Ops LLC increased its stake in shares of Evolus by 24.8% in the 2nd quarter. Squarepoint Ops LLC now owns 197,708 shares of the company's stock worth $1,372,000 after purchasing an additional 39,316 shares in the last quarter. California State Teachers Retirement System raised its holdings in Evolus by 79.9% in the 2nd quarter. California State Teachers Retirement System now owns 5,455 shares of the company's stock worth $38,000 after purchasing an additional 2,423 shares during the period. Finally, Angeles Wealth Management LLC bought a new position in shares of Evolus in the second quarter worth about $732,000. Hedge funds and other institutional investors own 90.69% of the company's stock.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company's flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.